Drug Discovery for Neurodegeneration

神经退行性疾病的药物发现

基本信息

批准号：
8256947
负责人：
Howard M. Fillit
金额：
$ 7.5万
依托单位：
ALZHEIMER'S DRUG DISCOVERY FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2007
资助国家：
美国
起止时间：
2007-09-15 至 2012-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8256947
关键词：
Academia Address Advanced Development Aging Alzheimer&apos s Disease Amyotrophic Lateral Sclerosis Area Basic Science Charge Collaborations Communities Development Discipline Disease Drug Delivery Systems Drug Design Drug Industry Education Evaluation Fostering Foundations Goals Grant Incidence Industry Innovative Therapy Investigation Journals Knowledge Lead Learning Marketing Minority Multiple Sclerosis NIH Program Announcements Nerve Degeneration Neurodegenerative Disorders Neurologic New York Outcome Parkinson Disease Participant Pharmaceutical Chemistry Pharmaceutical Preparations Phase Prevention Process Public Health Publishing Research Research Personnel Resource Sharing Resources Schedule Science Scientist Services Surveys Testing Time Training Translating U-Series Cooperative Agreements United States National Institutes of Health Update Validation Woman Work base commercialization drug development drug discovery effective therapy graduate student high throughput screening meetings nervous system disorder next generation novel novel therapeutics outreach posters pre-clinical pre-clinical research prevent programs public-private partnership quantum skills symposium web site

项目摘要

DESCRIPTION (provided by applicant): The Alzheimer's Drug Discovery Foundation (ADDF) requests a U13 Cooperative Agreement conference grant in support of its Drug Discovery for Neurodegeneration conference, scheduled for February 12-14, 2012 in New York, NY. The application is a competitive renewal of grant number: 2R13AG031125-o4. The purpose of the meeting is to advance drug discovery for neurodegenerative disease by training the next generation of scientific leaders on the process of translating basic research into novel therapeutics. Formal education on this topic is needed because there is a documented knowledge gap in this area of research and there are very few opportunities outside of the pharmaceutical industry to learn about these processes. The goals of this didactic conference are clearly consistent with the NIH's Roadmap: to bridge the knowledge gap in drug discovery and neurodegenerative disease; to bring together interdisciplinary scientists to stimulate new ways of combining skills and disciplines; to provide networking opportunities for these scientists to exchange ideas and resources; and to ultimately publish the proceedings in a scientific journal. This conference will give participants fundamental knowledge and resources on creating new drugs to treat and prevent neurodegenerative disease. It will address the barriers and challenges associated with the following sub-topics: Basics of Medicinal Chemistry; Early Phases of Drug Discovery; Preclinical Proof-of-Concept & Development; What is Druggable: Designing Drugs for CNS Target Classes; Commercialization Strategies: Developing Science into Products; and Resources and Services for Advancing Drug Discovery. Relevant examples for Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis will be included in the discussions. Sessions will consist of 3 to 5 presentations with ample time for Q&A, networking and poster sessions presented by young investigators. With respect to the public-private partnership initiative of the Roadmap, the ADDF will invite 28 internationally recognized scientists from academia, industry and NIH to serve as chairs or speakers. It is anticipated that this conference will serve 150 scientists from diverse backgrounds, including women, minorities, young/junior investigators and graduate students. PUBLIC HEALTH RELEVANCE: Relevance The public health problem the ADDF seeks to solve is to reduce the incidence of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. By offering this conference, the ADDF will increase scientists' knowledge of the drug discovery processes and catalyze them to work together to develop commercially viable and effective disease modifying therapies.

描述（由申请人提供）：阿尔茨海默氏症的药物发现基金会（ADDF）要求提供U13合作协议会议赠款，以支持其计划于2012年2月12日至14日在纽约州纽约市2月12日至14日举行的药物发现。该申请是授予编号的竞争续订：2R13AG031125-O4。会议的目的是通过训练下一代科学领导者在将基础研究转化为新型治疗剂的过程中，以推进神经退行性疾病的药物发现。需要对此主题进行正规教育，因为在这一研究领域存在有记录的知识差距，并且在制药行业之外，很少有机会了解这些过程。这次教学会议的目标显然与NIH的路线图：弥合药物发现和神经退行性疾病的知识差距；将跨学科的科学家汇集在一起，以刺激新的技能和学科的方式；为这些科学家提供交流思想和资源的网络机会；并最终在科学期刊上发布程序。这次会议将为参与者提供基础知识和创建新药来治疗和预防神经退行性疾病的资源。它将解决与以下子主题相关的障碍和挑战：药物化学的基础知识；药物发现的早期阶段；临床前概念证明与发展；什么是吸毒：为中枢神经系统目标类别设计药物；商业化策略：将科学发展成产品；以及用于推进药物发现的资源和服务。讨论中将包括有关阿尔茨海默氏病，帕金森氏病，肌萎缩性侧面硬化症和多发性硬化症的相关例子。会议将包括3到5个演讲，并有足够的时间进行问答，网络和海报会议，由年轻调查员提出。关于路线图的公私合作伙伴计划，ADDF将邀请28位来自学术界，工业和NIH的国际认可的科学家担任主席或演讲者。预计该会议将为来自不同背景的150名科学家提供服务，包括妇女，少数民族，年轻/初级调查员和研究生。公共卫生相关性：与ADDF寻求解决的公共卫生问题相关性是减少神经退行性疾病的发生率，例如阿尔茨海默氏病，帕金森氏病，肌萎缩性侧面硬化症和多发性硬化症。通过提供本次会议，ADDF将增加科学家对药物发现过程的了解，并促进它们共同开发商业可行有效的疾病修饰疗法。